Optimizing PTCy Dose and Timing

NCT03983850 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

105

Enrollment

NIH

Sponsor class

Conditions

Graft Versus Host Disease
Hematologic Neoplasms

Interventions

DRUG: Busulfan
DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Mycophenolate Mofetil
DRUG: Sirolimus

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]